

Listing of the Claims:

The following is a complete listing of all the claims in the application, with an indication of the status of each:

1-7. (Canceled)

8. (Currently amended) A method The use of a VEGF receptor gene or gene product for prophylaxis and inhibition of restenosis during and after angioplasty or preventing restenosis caused by a balloon catheter treatment of coronary blood vessels and treating conditions and diseases, in particular arteriosclerosis and ischemia, which are accompanied by overshooting neointimal proliferation, for promoting neovascularization and for supportive therapy in connection with shunts, for local treatment of areas of damage to the blood vessel endothelium, in particular before, during or after angioplasty, and for restenosis prophylaxis, comprising the step of providing a patient in need thereof with an effective quantity of a VEGF receptor gene or gene product.

9. (Currently amended) The method of use of a VEGF receptor gene or gene product as claimed in claim 8 wherein said patient is in need of for therapy in balloon catheter-assisted dilatation in connection with constricted coronary blood vessels.

10. (Currently Amended) The method of use as claimed in claim 8, wherein said a VEGF receptor gene is used in an expression vector.

11. (Currently Amended) The method of use as claimed in claim 10, wherein transient expression of the VEGF receptor is induced in said patient by said step of providing.

12. (Currently Amended) The method of use as claimed in claim 8 ‡, wherein the VEGF receptor gene or gene product is present in a form in which it is encapsulated by nanoparticles, microparticles or microspheres, in the form of a controlled release system or in the form of a solution.

13. (Currently Amended) The method of use as claimed in claim 8 †, wherein the VEGF receptor gene or gene product is impregnated in or on a stent or stored in an infiltration balloon catheter or a sideport balloon catheter.

14. (Canceled)